On February 20, 2019 Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, reported it will report its fourth quarter and full year 2018 financial results and business progress on Wednesday, February 27, 2019, after the close of the U.S. financial markets (Press release, Tocagen, FEB 20, 2019, View Source;p=RssLanding&cat=news&id=2388299 [SID1234533540]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Additionally, Marty Duvall, chief executive officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Friday, March 1, at 9:30 a.m. ET in New York City.

The live audio webcast from the conference and subsequent replay may be accessed by visiting Tocagen’s website. The webcast will be available shortly after conclusion of the presentation and archived on the company’s website for 90 days following the presentation.

To receive Tocagen’s press releases and other investor information, please visit the Investor Relations page of the company’s website and register for email alerts.